KNSA Kiniksa Pharmaceuticals International, plc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1730430 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY58.2%
TTM net income YoY205.1%
TTM EPS YoY193.3%
Revenue 3-yr CAGR56.1%
Net income 3-yr CAGR—
Margins
Gross margin90.2%
Operating margin13.8%
Net margin11.6%
FCF margin20.8%
EBITDA margin13.9%
Returns
ROE17.6%
ROA12.9%
ROIC (approx.)19.8%
Asset turnover1.12x
Leverage & solvency
Liabilities / assets27.8%
Debt / equity0.00x
Current ratio3.91x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.81x
Accruals ratio-10.5%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $285.97M | $243.60M | $214.27M | $202.13M | $180.85M | $156.80M | $137.78M | $122.54M |
| Cost of revenue | $27.76M | $23.57M | $20.80M | $20.95M | $20.26M | $18.60M | $17.87M | $17.90M |
| Gross profit | $258.21M | $220.03M | $193.47M | $181.18M | $160.60M | $138.19M | $119.92M | $104.64M |
| R&D expense | $32.79M | $40.90M | $27.48M | $34.61M | $24.17M | $18.75M | $19.32M | $35.22M |
| SG&A expense | $65.36M | $63.87M | $61.15M | $56.77M | $49.10M | $46.86M | $43.53M | $40.53M |
| Operating income | $54.24M | $27.19M | $29.27M | $19.77M | $24.02M | $20.16M | $13.27M | -$19.30M |
| Pretax income | $59.06M | $31.14M | $32.68M | $23.27M | $27.16M | $22.88M | $15.56M | -$16.98M |
| Income tax | $11.71M | $5.71M | $10.09M | $9.07M | $8.72M | $5.04M | $7.03M | -$8.09M |
| Net income | $47.34M | $25.43M | $22.59M | $14.20M | $18.43M | $17.83M | $8.54M | -$8.89M |
| EBITDA | $54.42M | $27.36M | $29.73M | $20.23M | $24.05M | $20.17M | $13.62M | -$18.90M |
| EPS (basic) | 0.61 | 0.33 | 0.30 | — | 0.25 | 0.24 | 0.12 | — |
| EPS (diluted) | 0.56 | 0.30 | 0.27 | — | 0.23 | 0.23 | 0.11 | — |
| Weighted avg. shares (diluted) | 84.92M | 83.40M | 82.41M | — | 80.04M | 77.94M | 76.15M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $81.66M | $175.68M | $189.95M | $165.60M | $174.86M | $192.04M | $157.13M | $183.58M |
| Short-term investments | $487.10M | $350.25M | $278.14M | $248.48M | $177.24M | $115.75M | $111.21M | $60.05M |
| Receivables | $30.78M | $23.49M | $23.22M | $15.59M | $51.74M | $31.91M | $40.06M | $41.72M |
| Inventory | $108.03M | $70.93M | $73.14M | $54.90M | $41.40M | $48.18M | $22.07M | $26.36M |
| Current assets | $750.10M | $668.63M | $594.17M | $527.18M | $475.53M | $420.31M | $355.91M | $331.80M |
| PP&E, net | $2.46M | $2.58M | $1.99M | $1.94M | $1.66M | $1.08M | $606,000 | $662,000 |
| Intangibles | $14.50M | $14.75M | $15.00M | $15.25M | $15.50M | $15.75M | $16.00M | $16.25M |
| Total assets | $983.24M | $896.11M | $825.28M | $763.63M | $712.33M | $661.15M | $599.33M | $580.55M |
| Current liabilities | $191.85M | $171.25M | $156.61M | $139.18M | $123.59M | $117.83M | $97.27M | $100.62M |
| Total liabilities | $273.05M | $241.96M | $219.59M | $196.03M | $176.95M | $166.14M | $141.84M | $142.12M |
| Shareholders' equity | $710.19M | $654.15M | $605.69M | $567.61M | $535.38M | $495.01M | $457.49M | $438.44M |
| Cash flow statement | ||||||||
| Operating cash flow | $47.55M | $47.20M | $50.20M | $53.89M | $33.68M | $28.09M | $22.32M | $18.77M |
| Capital expenditure | $180,000 | $663,000 | $161,000 | $633,000 | $671,000 | $165,000 | $99,000 | $193,000 |
| Free cash flow | $47.37M | $46.53M | $50.04M | $53.26M | $33.01M | $27.93M | $22.23M | $18.58M |
| Investing cash flow | -$138.56M | -$73.58M | -$31.92M | -$70.81M | -$62.76M | -$3.88M | -$51.54M | $65.29M |
| Financing cash flow | -$3.00M | $12.11M | $6.07M | $7.66M | $11.90M | $10.70M | $2.77M | $2.14M |
| Depreciation & amortization | $181,000 | $165,000 | $468,000 | $467,000 | $27,000 | $13,000 | $345,000 | $400,000 |
| Stock-based compensation | $13.06M | $11.64M | $10.06M | $10.23M | $10.14M | $8.88M | $7.75M | $8.30M |
Free plan shows the latest 8 periods; Pro shows all 38 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.